SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 19, 2001
(Exact name of registrant as specified in its charter)
DELAWARE 000-30231 76-0196733
(State or other jurisdiction (Commission File No.) (I.R.S. Employer
of incorporation) Identification No.)
10301 STELLA LINK, SUITE 110, HOUSTON, TEXAS 77025-5497
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: 713-578-4000
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
Genentech, Inc. made the following statements, among others, with respect to
Xolair(R) (or E25) in its webcast conference call held on January 18, 2001, to
discuss its fourth quarter results. Genentech feels that it remains on track for
a summer FDA approval and launch. Genentech is focused on ensuring that it
supplies the FDA with thorough and complete information on the non-clinical
studies of Xolair, as well as an update of the new platelet monitoring
information from its ALTO study (a 24-week safety study in patients with
difficult to treat asthma) so as to assure the best possible product labeling.
Genentech anticipates supplying the full set of information to the FDA in late
March. Genentech noted that it was possible that the time needed for it to
supply the information to the FDA and discuss the labeling for Xolair could push
the launch into the fall of 2001. However, Genentech said it has received no
feedback from FDA to suggest there will be any delay.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: January 19, 2001 TANOX, INC.
By: /s/ Michael A. Kelly
Michael A. Kelly
Vice President of Finance and CFO
© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission